Patrik Rorsman

Last updated

Patrik Rorsman
Professor Patrik Rorsman FMedSci FRS.jpg
Rorsman in 2014
Born (1959-05-14) 14 May 1959 (age 65) [1] [2]
NationalitySwedish [3]
Alma mater Uppsala University
Awards
Scientific career
Fields
Institutions
Thesis Patch-clamp studies on pancreatic glucagon- and insulin-secreting cells  (1986)
Doctoral advisor Bert Sakmann
Website ocdem.ox.ac.uk/patrik-rorsman

Patrik Rorsman (born 1959) [2] is a Swedish scientist who is Professor of Diabetic Medicine at the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), in the Radcliffe Department of Medicine at the University of Oxford [3] [6] [7] and a fellow of Harris Manchester College, Oxford. [8] [9]

Contents

Education

Rorsman was educated at Uppsala University in Sweden where he was awarded a PhD under the supervision of Nobel laureate Bert Sakmann in 1986 for patch clamp studies of pancreatic cells and their secretion of glucagon and insulin. [10]

Career

Rorsman was for short time the Canadian Excellence in Research Chair (CERC) in Diabetes [3] [11] [12] at the University of Alberta in Edmonton, before being reappointed a Professor at the University of Oxford in 2011. [3]

Research

Rorsman's research investigates exocytosis, ion channels and diabetes mellitus type 2. [5] [13] [14] [15] [16] [17] [18] [19] [20] [21] His research been funded by the Medical Research Council (MRC), [22] the Royal Society, the Wolfson Foundation, the Knut and Alice Wallenberg Foundation, [1] the Wellcome Trust and the Government of Canada. [9]

Awards and honours

Rorsman was elected a Fellow of the Royal Society (FRS) in 2014. His nomination reads:

Patrik Rorsman is an outstanding cell physiologist who has made distinguished contributions to our understanding of how the insulin- and glucagon-producing cells of the pancreatic islets regulate the plasma glucose concentration. His pioneering work is a shining example of post-genomic experimental diabetes research that integrates an unusual breadth of sophisticated methods and has clinical implications. It has led to the identification of key processes that become disrupted in type 2 diabetes, and shed light on the causal relationship between obesity and diabetes. He has also trained a school of excellent young investigators. [4]

Rorsman was elected a Fellow of the Academy of Medical Sciences (FMedSci) in 2010. His nomination reads:

Patrik Rorsman is Professor of Diabetic Medicine at the University of Oxford. He has been at the forefront of pancreatic islets research for more than 20 years. His work integrates an unusual variety and breadth of sophisticated high-resolution methods including the whole-islet patch-clamp technique which has helped to bridge the gap between patch-clamp measurements on isolated cultured cells and hormone release by whole islets. Patrik's work also covers human islet cells, which has revealed important differences between ß-cells in man and experimental animals that are likely to be highly relevant to the understanding of the causes and treatment of human diabetes. [23]

Rorsman was awarded the Minkowski Prize in 1996, the Göran Gustafsson Prize in 2003 and the Albert Renold Prize in 2013.[ citation needed ]

Related Research Articles

<span class="mw-page-title-main">Insulin</span> Peptide hormone

Insulin is a peptide hormone produced by beta cells of the pancreatic islets encoded in humans by the insulin (INS) gene. It is the main anabolic hormone of the body. It regulates the metabolism of carbohydrates, fats, and protein by promoting the absorption of glucose from the blood into cells of the liver, fat, and skeletal muscles. In these tissues the absorbed glucose is converted into either glycogen, via glycogenesis, or fats (triglycerides), via lipogenesis; in the liver, glucose is converted into both. Glucose production and secretion by the liver are strongly inhibited by high concentrations of insulin in the blood. Circulating insulin also affects the synthesis of proteins in a wide variety of tissues. It is thus an anabolic hormone, promoting the conversion of small molecules in the blood into large molecules in the cells. Low insulin in the blood has the opposite effect, promoting widespread catabolism, especially of reserve body fat.

<span class="mw-page-title-main">Pancreas</span> Organ of the digestive system and endocrine system of vertebrates

The pancreas is an organ of the digestive system and endocrine system of vertebrates. In humans, it is located in the abdomen behind the stomach and functions as a gland. The pancreas is a mixed or heterocrine gland, i.e., it has both an endocrine and a digestive exocrine function. 99% of the pancreas is exocrine and 1% is endocrine. As an endocrine gland, it functions mostly to regulate blood sugar levels, secreting the hormones insulin, glucagon, somatostatin and pancreatic polypeptide. As a part of the digestive system, it functions as an exocrine gland secreting pancreatic juice into the duodenum through the pancreatic duct. This juice contains bicarbonate, which neutralizes acid entering the duodenum from the stomach; and digestive enzymes, which break down carbohydrates, proteins and fats in food entering the duodenum from the stomach.

<span class="mw-page-title-main">Beta cell</span> Type of cell found in pancreatic islets

Beta cells (β-cells) are specialized endocrine cells located within the pancreatic islets of Langerhans responsible for the production and release of insulin and amylin. Constituting ~50–70% of cells in human islets, beta cells play a vital role in maintaining blood glucose levels. Problems with beta cells can lead to disorders such as diabetes.

<span class="mw-page-title-main">Pancreatic islets</span> Regions of the pancreas

The pancreatic islets or islets of Langerhans are the regions of the pancreas that contain its endocrine (hormone-producing) cells, discovered in 1869 by German pathological anatomist Paul Langerhans. The pancreatic islets constitute 1–2% of the pancreas volume and receive 10–15% of its blood flow. The pancreatic islets are arranged in density routes throughout the human pancreas, and are important in the metabolism of glucose.

<span class="mw-page-title-main">Glucagon</span> Peptide hormone

Glucagon is a peptide hormone, produced by alpha cells of the pancreas. It raises the concentration of glucose and fatty acids in the bloodstream and is considered to be the main catabolic hormone of the body. It is also used as a medication to treat a number of health conditions. Its effect is opposite to that of insulin, which lowers extracellular glucose. It is produced from proglucagon, encoded by the GCG gene.

<span class="mw-page-title-main">Delta cell</span>

Delta cells are somatostatin-producing cells. They can be found in the stomach, intestine and the pancreatic islets. Delta cells comprise ca 5% of the cells in the islets but may interact with many more islet cells than suggested by their low numbers. In rodents, delta-cells are located in the periphery of the islets; in humans the islet architecture is generally less organized and delta-cells are frequently observed inside the islets as well. In both species, the peptide hormone Urocortin III (Ucn3) is a major local signal that is released from beta cells to induce the local secretion of somatostatin. It has also been suggested that somatostatin may be implicated in insulin-induced hypoglycaemia through a mechanism involving SGLT-2 receptors. Ghrelin can also strongly stimulate somatostatin secretion, thus indirectly inhibiting insulin release. Viewed under an electron microscope, delta-cells can be identified as cells with smaller and slightly more compact granules than beta cells.

<span class="mw-page-title-main">Glucokinase</span> Enzyme participating to the regulation of carbohydrate metabolism

Glucokinase is an enzyme that facilitates phosphorylation of glucose to glucose-6-phosphate. Glucokinase occurs in cells in the liver and pancreas of humans and most other vertebrates. In each of these organs it plays an important role in the regulation of carbohydrate metabolism by acting as a glucose sensor, triggering shifts in metabolism or cell function in response to rising or falling levels of glucose, such as occur after a meal or when fasting. Mutations of the gene for this enzyme can cause unusual forms of diabetes or hypoglycemia.

<span class="mw-page-title-main">Alpha cell</span> Glucagon secreting cell

Alpha cells (α-cells) are endocrine cells that are found in the Islets of Langerhans in the pancreas. Alpha cells secrete the peptide hormone glucagon in order to increase glucose levels in the blood stream.

<span class="mw-page-title-main">Incretin</span> Group of gastrointestinal hormones

Incretins are a group of metabolic hormones that stimulate a decrease in blood glucose levels. Incretins are released after eating and augment the secretion of insulin released from pancreatic beta cells of the islets of Langerhans by a blood-glucose–dependent mechanism.

<span class="mw-page-title-main">Amylin</span> Peptide hormone that plays a role in glycemic regulation

Amylin, or islet amyloid polypeptide (IAPP), is a 37-residue peptide hormone. It is co-secreted with insulin from the pancreatic β-cells in the ratio of approximately 100:1 (insulin:amylin). Amylin plays a role in glycemic regulation by slowing gastric emptying and promoting satiety, thereby preventing post-prandial spikes in blood glucose levels.

<span class="mw-page-title-main">Type 1 diabetes</span> Form of diabetes mellitus

Type 1 diabetes (T1D), formerly known as juvenile diabetes, is an autoimmune disease that originates when cells that make insulin are destroyed by the immune system. Insulin is a hormone required for the cells to use blood sugar for energy and it helps regulate glucose levels in the bloodstream. It results in high blood sugar levels in the body prior to treatment. The common symptoms of this elevated blood sugar are frequent urination, increased thirst, increased hunger, weight loss, and other serious complications. Additional symptoms may include blurry vision, tiredness, and slow wound healing. Symptoms typically develop over a short period of time, often a matter of weeks if not months.

<span class="mw-page-title-main">Glucagon-like peptide-1</span> Gastrointestinal peptide hormone involved in glucose homeostasis

Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from the tissue-specific posttranslational processing of the proglucagon peptide. It is produced and secreted by intestinal enteroendocrine L-cells and certain neurons within the nucleus of the solitary tract in the brainstem upon food consumption. The initial product GLP-1 (1–37) is susceptible to amidation and proteolytic cleavage, which gives rise to the two truncated and equipotent biologically active forms, GLP-1 (7–36) amide and GLP-1 (7–37). Active GLP-1 protein secondary structure includes two α-helices from amino acid position 13–20 and 24–35 separated by a linker region.

An ATP-sensitive potassium channel is a type of potassium channel that is gated by intracellular nucleotides, ATP and ADP. ATP-sensitive potassium channels are composed of Kir6.x-type subunits and sulfonylurea receptor (SUR) subunits, along with additional components. KATP channels are widely distributed in plasma membranes; however some may also be found on subcellular membranes. These latter classes of KATP channels can be classified as being either sarcolemmal ("sarcKATP"), mitochondrial ("mitoKATP"), or nuclear ("nucKATP").

Dame Frances Mary Ashcroft is a British ion channel physiologist. She is Royal Society GlaxoSmithKline Research Professor at the University Laboratory of Physiology at the University of Oxford. She is a fellow of Trinity College, Oxford, and is a director of the Oxford Centre for Gene Function. Her research group has an international reputation for work on insulin secretion, type II diabetes and neonatal diabetes. Her work with Andrew Hattersley has helped enable children born with diabetes to switch from insulin injections to tablet therapy.

<span class="mw-page-title-main">Blood sugar regulation</span> Hormones regulating blood sugar levels

Blood sugar regulation is the process by which the levels of blood sugar, the common name for glucose dissolved in blood plasma, are maintained by the body within a narrow range.

<span class="mw-page-title-main">Glucagon-like peptide-1 receptor</span> Receptor activated by peptide hormone GLP-1

The glucagon-like peptide-1 receptor (GLP1R) is a G protein-coupled receptor (GPCR) found on beta cells of the pancreas and on neurons of the brain. It is involved in the control of blood sugar level by enhancing insulin secretion. In humans it is synthesised by the gene GLP1R, which is present on chromosome 6. It is a member of the glucagon receptor family of GPCRs. GLP1R is composed of two domains, one extracellular (ECD) that binds the C-terminal helix of GLP-1, and one transmembrane (TMD) domain that binds the N-terminal region of GLP-1. In the TMD domain there is a fulcrum of polar residues that regulates the biased signaling of the receptor while the transmembrane helical boundaries and extracellular surface are a trigger for biased agonism.

The insulin transduction pathway is a biochemical pathway by which insulin increases the uptake of glucose into fat and muscle cells and reduces the synthesis of glucose in the liver and hence is involved in maintaining glucose homeostasis. This pathway is also influenced by fed versus fasting states, stress levels, and a variety of other hormones.

Mladen Vranic, MD, DSc, O.C., O.Ont, FRSC, FRCP(C), FCAHS, Canadian Medical Hall of Fame[CMHF] April 3, 1930 – June 18, 2019, was a Croatian-born diabetes researcher, best known for his work in tracer methodology, exercise and stress in diabetes, the metabolic effects of hormonal interactions, glucagon physiology, extrapancreatic glucagon, the role of the direct and indirect metabolic effects of insulin and the prevention of hypoglycemia. Vranic was recognized by a number of national and international awards for his research contributions, mentoring and administration including the Orders of Canada (Officer) and Ontario.

<span class="mw-page-title-main">Daniel J. Drucker</span> Canadian endocrinologist (born 1956)

Daniel Joshua Drucker is a Canadian endocrinologist. A Fellow of the Royal Society, he is a professor of medicine at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto. He is known for his research into intestinal hormones and their use in the treatment of diabetes, obesity, and other metabolic diseases, as well as intestinal failure.

Charles Nicholas "Nick" Hales was an English physician, biochemist, diabetologist, pathologist, and professor of clinical biochemistry

References

  1. 1 2 3 Wallenberg researcher aiming to solve the riddle of diabetes, akademimiliv.se
  2. 1 2 "RORSMAN, Prof. Patrik" . Who's Who . Vol. 2017 (online Oxford University Press  ed.). Oxford: A & C Black.(Subscription or UK public library membership required.)
  3. 1 2 3 4 Gewin, V. (2012). "Turning point: Patrik Rorsman". Nature. 492 (7428): 301. doi: 10.1038/nj7428-301a .
  4. 1 2 "Professor Patrik Rorsman FMedSci FRS". London: The Royal Society. Archived from the original on 4 November 2014.
  5. 1 2 Professor Patrik Rorsman (OXION Member), University of Oxford
  6. Patrik Rorsman's publications indexed by the Scopus bibliographic database. (subscription required)
  7. Patrik Rorsman publications indexed by Microsoft Academic
  8. Professor Patrik Rorsman, Harris Manchester College, University of Oxford
  9. 1 2 Patrik Rorsman leaves $10M Edmonton research grant behind, returns to England, National Post , 2012-11-14
  10. Rorsman, Patrik (1986). Patch-clamp studies on pancreatic glucagon- and insulin-secreting cells (PhD thesis). Uppsala University.
  11. The value of the Canada Excellence Research Chairs (CERC) program, The Lab and Field
  12. Patrik Rorsman is the new Canada Excellence Research Chair in Diabetes on YouTube, University of Alberta
  13. Ashcroft, F. M.; Rorsman, P. (1989). "Electrophysiology of the pancreatic β-cell". Progress in Biophysics and Molecular Biology. 54 (2): 87–143. doi: 10.1016/0079-6107(89)90013-8 . PMID   2484976.
  14. Poy, M. N.; Eliasson, L.; Krutzfeldt, J.; Kuwajima, S.; Ma, X.; MacDonald, P. E.; Pfeffer, S. B.; Tuschl, T.; Rajewsky, N.; Rorsman, P.; Stoffel, M. (2004). "A pancreatic islet-specific microRNA regulates insulin secretion". Nature. 432 (7014): 226–30. Bibcode:2004Natur.432..226P. doi:10.1038/nature03076. PMID   15538371. S2CID   4415988.
  15. Rorsman, P.; Renstrom, E. (2003). "Insulin granule dynamics in pancreatic beta cells". Diabetologia. 46 (8): 1029–45. doi: 10.1007/s00125-003-1153-1 . PMID   12879249.
  16. Ämmälä, C.; Ashcroft, F. M.; Rorsman, P. (1993). "Calcium-independent potentiation of insulin release by cyclic AMP in single β-cells". Nature. 363 (6427): 356–358. Bibcode:1993Natur.363..356A. doi:10.1038/363356a0. PMID   7684514. S2CID   4341009.
  17. Rorsman, P.; Berggren, P. O.; Bokvist, K.; Ericson, H.; Möhler, H.; Östenson, C. G. R.; Smith, P. A. (1989). "Glucose-inhibition of glucagon secretion involves activation of GABAA-receptor chloride channels". Nature. 341 (6239): 233–6. Bibcode:1989Natur.341..233R. doi:10.1038/341233a0. PMID   2550826. S2CID   699135.
  18. MacDonald, P. E.; Joseph, J. W.; Rorsman, P. (2005). "Glucose-sensing mechanisms in pancreatic -cells". Philosophical Transactions of the Royal Society B: Biological Sciences. 360 (1464): 2211–25. doi:10.1098/rstb.2005.1762. PMC   1569593 . PMID   16321791.
  19. Gerken, T.; Girard, C. A.; Tung, Y. -C. L.; Webby, C. J.; Saudek, V.; Hewitson, K. S.; Yeo, G. S. H.; McDonough, M. A.; Cunliffe, S.; McNeill, L. A.; Galvanovskis, J.; Rorsman, P.; Robins, P.; Prieur, X.; Coll, A. P.; Ma, M.; Jovanovic, Z.; Farooqi, I. S.; Sedgwick, B.; Barroso, I.; Lindahl, T.; Ponting, C. P.; Ashcroft, F. M.; O'Rahilly, S.; Schofield, C. J. (2007). "The Obesity-Associated FTO Gene Encodes a 2-Oxoglutarate-Dependent Nucleic Acid Demethylase". Science. 318 (5855): 1469–1472. Bibcode:2007Sci...318.1469G. doi:10.1126/science.1151710. PMC   2668859 . PMID   17991826.
  20. Patrik Rorsman: Diabetes and Insulin Secretion on YouTube, University of Oxford
  21. Interview with Patrik Rorsman on YouTube, Scandinavian Physiological Society
  22. UK Government research grants awarded to Patrik Rorsman, via Research Councils UK
  23. "Professor Patrik Rorsman FRS FMedSci". London: The Academy of Medical Sciences. Archived from the original on 4 November 2014.